Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Silence Therapeutics bolsters board

Silence Therapeutics has hired Stuart Collinson as a non-executive director as Simon Sturge resigns to take up other business commitments
Silence Therapeutics bolsters board
Experienced Collinson, 55, has held senior management roles at GlaxoWellcome, now GlaxoSmithKline and Baxter International...

Silence Therapeutics (LON:SLN) has hired Stuart Collinson as a non-executive director as Simon Sturge resigns to take up other business commitments.

Experienced Collinson, 55, has held senior management roles at GlaxoWellcome, now GlaxoSmithKline and Baxter International and was chairman, chief executive and president of previously listed Aurora Biosciences, which was acquired by Vertex Pharmaceuticals (NASDAQ:VRTX) in 2001.

He has held various positions in public and private life science companies in the US and Europe and is a partner of Forward Ventures, a biopharmaceutical venture capital fund.

Ali Mortazavi, the chief executive of Silence Therapeutics, said: "We are very pleased to welcome Stuart to our board, who brings with him extensive experience in the sector with a business development and M&A track record across the US and Europe."

Shares were unchanged at 137.875p.

Giles_55af4ddca6481.jpg
Why Invest In Silence Therapeutics plc? Read More Here

Register here to be notified of future SLN Company articles
View full SLN profile

Silence Therapeutics plc Timeline

Related Articles

immupharma-_kiss_pic_with_mum.png
March 01 2016
Lupuzor is not the only part of the Immupharma story and McCarthy plans also to raise the profile of the rest of the group's early stage pipeline in 2016.....
Magnified view of cancer cells
July 28 2016
ANGLE's Parsortix blood screening system could replace the traditional biopsy in the diagnosis of breast cancer. Proactive takes a look at how it works and the potential it holds to change the way cancer is diagnosed.
viagra2.jpg
September 07 2016
It means Futura now has a differentiated product in a market worth US$5bn that , currently dominated by top-selling drugs, such as Viagra and Cialis, that have limitations.

© Proactive Investors 2016

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.